Response to comment on “CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy”

Key Points

• The aim is to evaluate how CYP2C19 genotyping affects responses to mavacamten in patients with obstructive hypertrophic cardiomyopathy based on metabolic status.
• Analysis of CYP2C19 genotypes in patients with obstructive hypertrophic cardiomyopathy.
• Comparison of treatment outcomes for normal, intermediate, and rapid metabolisers.
• Review of previous responses and outcomes related to genotyping.
• Comments indicate varying outcomes in patients based on CYP2C19 metabolism types.
• Highlight the need for tailored treatment approaches based on metabolic profiles.